Stavanger University Hospital

Running trials

• Not yet recruiting

  Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism

  NCT07816978· Phase 4· Sahlgrenska University Hospital· Source

• Recruiting

  Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET)

  2025-521330-29-00· Phase 2· Ostfold Hospital Trust· Source

• Not yet recruiting

  NURSE-led Geriatric Assessment in Older Colorectal Cancer Patients

  NCT07872787· Helse Stavanger HF· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  Implementing the 6th Generation Cardiac Troponin T

  NCT07936630· Rasmus Bo Hasselbalch· Source

• Not yet recruiting

  Detecting Liver Fibrosis in Patients At-risk

  NCT07775638· Helse Stavanger HF· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis

  2024-513927-18-00· Phase 2· Oslo University Hospital HF· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· Phase 3· European Myeloma Network B.V.· Source

• Recruiting

  Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.

  2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Recruiting

  Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study

  2023-505573-32-00· Phase 3· Ostfold Hospital Trust· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

  NCT07001800· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· BioNTech SE· Source

• Recruiting

  The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind trial (NorMig)

  2024-517981-40-00· Phase 3· Oslo University Hospital HF· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  Bridging Affect Consciousness, Mentalization and Trauma- Exploring an Integrative Treatment Approach for Personality Disorder (PD).

  NCT06983002· Helse Stavanger HF· Source

• Recruiting

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

  NCT06929806· Phase 3· Pharmacosmos A/S· Source

• Recruiting

  Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)

  2024-511346-39-00· Phase 1· Chugai Pharmaceutical Co. Ltd.· Source

• Recruiting

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Thrombolysis in Factor Xa-inhibitors Trial

  NCT06878066· Phase 3· Guri Hagberg· Source

• Recruiting

  Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

  NCT06419946· Phase 3· Vastra Gotaland Region· Source

• Recruiting

  The Norwegian Immunotherapy in Multiple Myeloma Study

  NCT06855121· St. Olavs Hospital· Source

• Recruiting

  Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)

  2023-506998-35-00· Phase 3· Vaestra Goetalandsregionen· Source

• Recruiting

  Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

  NCT06488482· Phase 3· Uppsala University· Source

• Enrolling by invitation

  Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

  NCT06723106· Phase 1· Chugai Pharmaceutical· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer

  NCT06944587· Oslo University Hospital· Source

• Recruiting

  Management of Patients With Heart Failure at Home After Hospital Discharge

  NCT06576752· University Hospital, Akershus· Source

• Active, not recruiting

  DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients

  NCT04392504· Phase 1/2· Oslo University Hospital Hf· Source

• Recruiting

  The Key to Integrated Trauma Treatment in Psychosis Trial

  NCT06608706· Haukeland University Hospital· Source

• Active, not recruiting

  Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: The Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)

  2023-510184-35-00· Phase 4· Diakonhjemmet Sykehus AS· Source

• Active, not recruiting

  Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)

  NCT06440629· Phase 4· Diakonhjemmet Hospital· Source

• Recruiting

  Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

  NCT06371417· Phase 1· Chugai Pharmaceutical· Source

• Recruiting

  Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)

  NCT06362707· Phase 2· Helse Stavanger HF· Source

• Active, not recruiting

  A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06468228· Phase 3· AbbVie· Source

Showing 50 of 115.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer4 recruiting
• Multiple myeloma4 recruiting
• Acute myeloid leukaemia3 recruiting
• ALS (motor neurone disease)3 recruiting
• Immune thrombocytopenia (ITP)3 recruiting
• Pancreatic cancer3 recruiting
• Alzheimer disease2 recruiting
• Antiphospholipid syndrome2 recruiting
• Atrial fibrillation2 recruiting
• Chronic kidney disease2 recruiting
• Colorectal cancer2 recruiting
• Depression2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Glioblastoma2 recruiting
• Heart failure2 recruiting
• Lung cancer2 recruiting
• Prostate cancer2 recruiting
• Stroke2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 1 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Aortic stenosis1 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hearing loss1 recruiting
• High blood pressure1 recruiting
• IgA nephropathy1 recruiting
• Lewy body dementia1 recruiting
• Long COVID and ME/CFS1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Multiple sclerosis1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Peripheral artery disease1 recruiting
• Schizophrenia1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A PHASE 1B DOSE RANGE FINDING STUDY OF PHENSERINE COMPARED TO DONEPEZIL IN PARTICIPANTS WITH EARLY OR MILD ALZHEIMER’S DISEASE

  2023-510282-10-00· Phase 1· Helse Stavanger HF· Source

• Completed

  Phenserine on the Alzheimer's Treatment Horizon, Study 1

  NCT06774261· Phase 1· Helse Stavanger HF· Source

• Completed

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· Phase 2· Novo Nordisk A/S· Source

• Completed

  EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

  NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  The TAF-MS study

  2023-503814-62-00· Phase 2· Helse Bergen HF· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Bacillus Subtilis in Parkinson's Disease

  NCT06487975· University of Edinburgh· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study)

  2022-501850-12-00· Phase 2· Arctic Bioscience AS· Source

• Completed

  Online Cognitive Behavioral Therapy for Depressive Symptoms in Parkinson's Disease

  NCT05585827· Helse Stavanger HF· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Recruiting

  Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

  NCT05344209· Phase 2· Vestre Viken Hospital Trust· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  NCT05173987· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

  NCT05002569· Phase 3· Bristol Myers Squibb International Corporation· Source

• Completed

  A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

  NCT03992430· Phase 3· Sarepta Therapeutics, Inc.· Source

• Completed

  UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

  NCT04382664· Phase 2· Ultimovacs ASA· Source

• Completed

  The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study

  NCT04122235· Sorlandet Hospital HF· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Terminated

  "Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.

  NCT03402477· Helse Stavanger HF· Source

• Completed

  Aspirin in Colorectal Cancer Liver Metastases

  NCT03326791· Phase 2/3· Oslo University Hospital· Source

• Completed

  A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

  NCT02100722· Stanford University· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lewy body dementia18 works · 1 trial